MPA
PFE icon

Marvin & Palmer Associates’s Pfizer PFE Stock Holding History

Marvin & Palmer Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-116,078
Closed -$4.81M – 33
2018
Q4 		$4.81M Buy
+116,078
New +$4.82M 4.14% 13

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Marvin & Palmer Associates's PFE Position: Q1 2019 in Review

Marvin & Palmer Associates sold out of Pfizer (PFE) in Q1 2019, closing a stake of 116,078 shares — an estimated $4.81M sold.

Marvin & Palmer Associates first reported a position in PFE in Q4 2018 and held it in 1 quarter. The position peaked at $4.81M in Q4 2018. 2,392 funds tracked by Wall St. Rank hold PFE as of Q1 2019.

  • Marvin & Palmer Associates reported no remaining Pfizer position as of Q1 2019 after selling out during the quarter.
  • Marvin & Palmer Associates sold 116,078 Pfizer shares in Q1 2019, an estimated $4.81M.
  • Marvin & Palmer Associates first reported a position in Pfizer in Q4 2018 and held it in 1 quarter.
  • Marvin & Palmer Associates's Pfizer position peaked at $4.81M in Q4 2018.
  • 2,392 funds tracked by Wall St. Rank held Pfizer as of Q1 2019.

Based on Marvin & Palmer Associates's 13F filing for Q1 2019, filed 13 May 2019.